Jump to content

Ruthenium anti-cancer drugs

Add links
From Wikipedia, the free encyclopedia
(Redirected from Ruthenium diamine complexes)

Ruthenium anti-cancer drugs are coordination complexes of ruthenium complexes that have anticancer properties. They promise to provide alternatives to platinum-based drugs for anticancer therapy.[1][2] No ruthenium anti-cancer drug has been commercialized.

Since 1979, when Cisplatin entered clinical trials, there has been continuing interest in alternative metal-based drugs.[3] The leading ruthenium-based candidates are BOLD-100 and TLD-1433. Other ruthenium based therapeutics that have been tested clinically include NAMI-A and KP1019. The first ruthenium-based drug to enter clinical trials was NAMI-A. More ruthenium drugs are still under development. Ruthenium complexes as anticancer drugs were originally designed to mimic platinum drugs for targeting DNA,[4] but emerging ruthenium compounds have shown a variety of mechanisms of actions, which include ROS generation, and as Endoplasmic reticulum stress agents.[5]

Properties of ruthenium complexes

[edit]

Ruthenium has numerous properties that qualify it as an antineoplastic drug contender.[4][6]

Oxidation states and geometry

[edit]

Ruthenium complexes typically adopt oxidation states II and III[7] The geometry assumed by most ruthenium complexes is octahedral, which differs from the square planar molecular geometry typical for platinum(II). The presence of six ligands allows for tuning of the complexes' electronic and steric properties.[1][8][9] Its partially filled 4d sub-shell allows it to form complexes that are useful for a wide variety of applications including catalysis, electronics, photochemistry, biosensors and anticancer drugs.[10][11]

Ligand exchange rates

[edit]

The rate of ligand exchange for ruthenium complexes is relatively slow in comparison with other transition metal complexes. The range of these exchange rates is around 10−2 to 10−4 s−1 which is on the scale of an average cell’s lifetime, giving the drug high kinetic stability and minimizing side reactions.[1] This allows the Ru complex to remain intact as it approaches the target as well as remain viable throughout its interaction with the cells. It is also possible through ligand variation to precisely tune the exchange kinetics, allowing a large degree of control over the complex’s stability.[12]

Activation

[edit]

The theory of "activation by reduction" is based on the understanding that Ru(II) complexes are generally more reactive than Ru(III) complexes. As cancer cells are generally growing and multiplying much more rapidly than normal healthy cells, this creates an environment that is less oxygen-rich due to the raised metabolic rate. When this is paired with the tendency of cancerous cells to contain higher levels of glutathione and a lower pH, a chemically reducing environment is created.[1] This theoretically allows for ruthenium complexes to be administered as much less active, non-toxic Ru(III) compounds (as a prodrug), which can be activated solely at the site of the cancerous cells.[1] The reduction is thought to occur by mitochondrial proteins or microsomal single electron transfer proteins, though it may also occur by trans-membrane electron transport systems which reside outside the cell – implying that entry to the cancerous cells may not be required for the drug to be effective.[7] In theory it is also possible for the ruthenium compounds to be oxidized back to their inactive form if it leaves the cancerous environment. This phenomenon remains a theory, and has been primarily demonstrated in vitro.[4]

Although this theory is attractive, convenient, and grounded in fundamental ruthenium chemistry, this theory falls apart when investigated under in vivo. A direct contradiction of this theory was proven using XANES and BOLD-100. This study examined several tissues (tumor included) of SW480-bearing mice for 24 hours after administration of BOLD-100. This study showed that the Ru(III) oxidation state persists, and since BOLD-100 has significant biological effects within that 24-hour time point, this directly contradicts the "activation by reduction" mechanism.[13]

Biological transportation

[edit]
3D rendering of human serum albumin (HSA)

The ruthenium complex BOLD-100 binds to serum albumin as established by X-ray crystallography. This adduct is proposed to facilitate uptake.[14] The levels of serum albumin in these cancerous cells are greatly increased, which may contribute to the lower toxicity associated to the ruthenium drugs in comparison to platinum.[12]

Prospective ruthenium anti-cancer drugs

[edit]

BOLD-100

[edit]

BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is the most clinically advanced ruthenium-based therapeutic. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX.[15]

NAMI

[edit]
Chemical structure of sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)] (BOLD-100)

NAMI {Na[trans-RuCl4](DMSO)(imida)]} and NAMI-A {H2Im[trans-RuCl4(DMSO)HIm[imidH] are salts that were investigated as anti-cancer drugs.[6] NAMI-A is considered a pro-drug and is inactive at physiological pH of 7.4.[1] Cancer cells generally contain a lower oxygen concentration as well as higher levels of glutathione and a lower pH than normal tissues creating a reducing environment. Upon entering cancer cells NAMI-A is activated by the reduction of Ru(III) to Ru(II) to form the active anti-cancer agent.[citation needed]

KP1019

[edit]

KP1019, a salt of trans-tetrachlorobis(indazole)ruthenate(III) were investigated as drugs.[16] KP1019 has an octahedral structure with two trans N-donor indazole and four chloride ligands in the equatorial plane.[17][18][19] It has a low solubility in water, which makes it difficult to transport in the bloodstream. Instead KP1339[clarification needed] is used as a preparation of KP1019 in clinical trials, since it has a better solubility as a sodium salt.[19]

Proteins and other N-donors are good binding partners for KP1019.[20][21][22]

Especially transferrin and albumin are good binding partners.[23] The overall method of action for KP1019 needs to be supported further.

Tumor cells have a high requirement of iron, which results in a large concentration of transferrin. Ru(III) complexes bind to transferrin and are proposed to interfere with iron uptake.[24][25]

RAPTA

[edit]

RAPTA compounds are ruthenium–arene complexes bearing the 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane ligand.[26] The complex has a piano stool geometry. The PTA ligand confers water solubility, and the two chloride ligands are labile.[8] RAPTA compounds have low general toxicity that apparently reduces the side-effects associated with chemotherapy.[8]

RAED

[edit]

Ruthenium diamine complexes have been investigated as potential anticancer drugs.[27][28] RAED compounds are ruthenium–arene complexes bearing the 1,2-ethylenediamine ligand.

The ruthenium diamine complexes form adducts with guanine.[29] Methylation or substitution on en-NH, which prevent the hydrogen bonding, can lead to the loss of cytotoxic activity of the complex toward cancer cell.[30][31] The ethylenediamine ligand suppresses reactions of the complex with amino acid residues. The Ru(II) complexes have a higher affinity to DNA in the presence of protein than the Ru(III) compounds, such as NAMI-A.[32]

References

[edit]
  1. ^ a b c d e f Antonarakis, Emmanuel S.; Emadi, Ashkan (2010). "Ruthenium-based chemotherapeutics: Are they ready for prime time?". Cancer Chemotherapy and Pharmacology. 66 (1): 1–9. doi:10.1007/s00280-010-1293-1. PMC 4020437. PMID 20213076.
  2. ^ Bergamo, A.; Gaiddon, C.; Schellens, J.H.M.; Beijnen, J.H.; Sava, G. (2012). "Approaching tumour therapy beyond platinum drugs". Journal of Inorganic Biochemistry. 106 (1): 90–9. doi:10.1016/j.jinorgbio.2011.09.030. PMID 22112845.
  3. ^ Clarke, M.J.; Bitler, S.; Rennert, D.; Buchbinder, M.; Kelman, A.D. (1980). "Reduction and Subsequent Binding of Ruthenium Ions Catalyzed by Subcellular Components". Journal of Inorganic Biochemistry. 12 (1): 79–87. doi:10.1016/S0162-0134(00)80045-8. PMID 7373292.
  4. ^ a b c Bergamo, Alberta; Sava, Gianni (2011). "Ruthenium anticancer compounds: Myths and realities of the emerging metal-based drugs". Dalton Transactions. 40 (31): 7817–23. doi:10.1039/C0DT01816C. PMID 21629963.
  5. ^ Mjos, Katja Dralle; Orvig, Chris (2014-04-23). "Metallodrugs in Medicinal Inorganic Chemistry". Chemical Reviews. 114 (8): 4540–4563. doi:10.1021/cr400460s. ISSN 0009-2665. PMID 24456146.
  6. ^ a b Amin, Amr; Buratovich, Michael (2009). "New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field". Mini-Reviews in Medicinal Chemistry. 9 (13): 1489–503. doi:10.2174/138955709790361566. PMID 20205631.
  7. ^ a b Page, Simon (1 January 2012). "Ruthenium compounds as anticancer agents". Education in Chemistry. Vol. 49, no. 1. Royal Society of Chemistry. pp. 26–29.
  8. ^ a b c Ang, Wee Han; Casini, Angela; Sava, Gianni; Dyson, Paul J. (2011). "Organometallic ruthenium-based antitumor compounds with novel modes of action". Journal of Organometallic Chemistry. 696 (5): 989–98. doi:10.1016/j.jorganchem.2010.11.009.
  9. ^ Gopal YN, Jayaraju D, Kondapi AK (April 1999). "Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action". Biochemistry. 38 (14): 4382–8. doi:10.1021/bi981990s. PMID 10194357.
  10. ^ Kostova I (2006). "Ruthenium complexes as anticancer agents". Current Medicinal Chemistry. 13 (9): 1085–107. doi:10.2174/092986706776360941. PMID 16611086.
  11. ^ Antonarakis ES, Emadi A (May 2010). "Ruthenium-based chemotherapeutics: are they ready for prime time?". Cancer Chemotherapy and Pharmacology. 66 (1): 1–9. doi:10.1007/s00280-010-1293-1. PMC 4020437. PMID 20213076.
  12. ^ a b Bruijnincx, Pieter C.A.; Sadler, Peter J. (2009). Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Advances in Inorganic Chemistry. Vol. 61. pp. 1–62. doi:10.1016/S0898-8838(09)00201-3. ISBN 9780123750334. PMC 3024542. PMID 21258628.
  13. ^ Blazevic, Amir; Hummer, Alfred A.; Heffeter, Petra; Berger, Walter; Filipits, Martin; Cibin, Giannantonio; Keppler, Bernhard K.; Rompel, Annette (23 January 2017). "Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse". Scientific Reports. 7 (1): 40966. Bibcode:2017NatSR...740966B. doi:10.1038/srep40966. PMC 5256101. PMID 28112202.
  14. ^ Bijelic, Aleksandar; Theiner, Sarah; Keppler, Bernhard K.; Rompel, Annette (23 June 2016). "X-ray Structure Analysis of Indazolium trans- [Tetrachlorobis(1 H -indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism". Journal of Medicinal Chemistry. 59 (12): 5894–5903. doi:10.1021/acs.jmedchem.6b00600. PMC 4921950. PMID 27196130.
  15. ^ Clinical trial number NCT04421820 NCT04421820 for "BOLD-100 in combination with FOLFOX for the treatment of advanced solid tumours." at ClinicalTrials.gov
  16. ^ Galanski, M.; Arion, V.; Jakupec, M.; Keppler, B. (2003). "Recent Developments in the Field of Tumor-Inhibiting Metal Complexes". Current Pharmaceutical Design. 9 (25): 2078–89. doi:10.2174/1381612033454180. PMID 14529417. S2CID 9170949.
  17. ^ Peti, Wolfgang; Pieper, Thomas; Sommer, Martina; Keppler, Bernhard K.; Giester, Gerald (1999). "Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt". European Journal of Inorganic Chemistry. 1999 (9): 1551–5. doi:10.1002/(SICI)1099-0682(199909)1999:9<1551::AID-EJIC1551>3.0.CO;2-7.
  18. ^ Jakupec, M. A.; Galanski, M.; Keppler, B. K. (2003). "Tumour-inhibiting platinum complexes—state of the art and future perspectives". Reviews of Physiology, Biochemistry and Pharmacology. Vol. 146. pp. 1–53. doi:10.1007/s10254-002-0001-x. ISBN 978-3-540-00228-4. PMID 12605304.
  19. ^ a b Hartinger, Christian G.; Zorbas-Seifried, Stefanie; Jakupec, Michael A.; Kynast, Bernd; Zorbas, Haralabos; Keppler, Bernhard K. (2006). "From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)". Journal of Inorganic Biochemistry. 100 (5–6): 891–904. doi:10.1016/j.jinorgbio.2006.02.013. PMID 16603249.
  20. ^ Egger, Alexander; Arion, Vladimir B.; Reisner, Erwin; Cebrián-Losantos, Berta; Shova, Sergiu; Trettenhahn, Günter; Keppler, Bernhard K. (2005). "Reactions of Potent Antitumor Complex trans-[RuIIICl4(indazole)2]− with a DNA-Relevant Nucleobase and Thioethers: Insight into Biological Action". Inorganic Chemistry. 44 (1): 122–32. doi:10.1021/ic048967h. PMID 15627368.
  21. ^ Smith, Clyde A.; Sutherland-Smith, Andrew J.; Kratz, Felix; Baker, E. N.; Keppler, B. H. (1996). "Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses". Journal of Biological Inorganic Chemistry. 1 (5): 424–31. doi:10.1007/s007750050074. S2CID 10270542.
  22. ^ Trynda-Lemiesz, Lilianna; Karaczyn, Aldona; Keppler, Bernhard K; Kozlowski, Henryk (2000). "Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III)". Journal of Inorganic Biochemistry. 78 (4): 341–6. doi:10.1016/S0162-0134(00)00062-3. PMID 10857915.
  23. ^ Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. (2005). "Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins". Journal of Analytical Atomic Spectrometry. 20 (9): 856–63. doi:10.1039/B508060F.
  24. ^ Kratz, F; Hartmann, M; Keppler, B; Messori, L (1994). "The binding properties of two antitumor ruthenium(III) complexes to apotransferrin". The Journal of Biological Chemistry. 269 (4): 2581–8. doi:10.1016/S0021-9258(17)41984-3. PMID 8300587.
  25. ^ Pongratz, Martina; Schluga, Petra; Jakupec, Michael A.; Arion, Vladimir B.; Hartinger, Christian G.; Allmaier, Günter; Keppler, Bernhard K. (2004). "Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy". Journal of Analytical Atomic Spectrometry. 19: 46–51. doi:10.1039/B309160K.
  26. ^ Tan, Yu Qian; Dyson, Paul J.; Ang, Wee Han (2011). "Acetal-Functionalized RAPTA Complexes for Conjugation and Labeling". Organometallics. 30 (21): 5965–71. doi:10.1021/om200783r.
  27. ^ Morris, Robert E.; Aird, Rhona E.; del Socorro Murdoch, Piedad; Chen, Haimei; Cummings, Jeff; Hughes, Nathan D.; Parsons, Simon; Parkin, Andrew; Boyd, Gary; Jodrell, Duncan I.; Sadler, Peter J. (2001). "Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes". Journal of Medicinal Chemistry. 44 (22): 3616–3621. doi:10.1021/jm010051m. ISSN 0022-2623. PMID 11606126.
  28. ^ Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO, Sadler PJ (2002). "Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts". Journal of the American Chemical Society. 124 (12): 3064–82. doi:10.1021/ja017482e. PMID 11902898.
  29. ^ Chen H, Parkinson JA, Morris RE, Sadler PJ (2003). "Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms". Journal of the American Chemical Society. 125 (1): 173–86. doi:10.1021/ja027719m. PMID 12515520.
  30. ^ Bugarcic T, Habtemariam A, Deeth RJ, Fabbiani FP, Parsons S, Sadler PJ (2009). "Ruthenium(II) arene anticancer complexes with redox-active diamine ligands". Inorganic Chemistry. 48 (19): 9444–53. doi:10.1021/ic9013366. PMID 19780621.
  31. ^ Habtemariam A, Melchart M, Fernandez R, Parsons S, Oswald ID, Parkin A, Fabbiani FP, Davidson JE, Dawson A, Aird RE, Jodrell DI, Sadler PJ (2006). "Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands". Journal of Medicinal Chemistry. 49 (23): 6858–68. doi:10.1021/jm060596m. PMID 17154516.
  32. ^ Wang F, Chen H, Parkinson JA, Murdoch Pdel S, Sadler PJ (2002). "Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine". Inorganic Chemistry. 41 (17): 4509–23. doi:10.1021/ic025538f. PMID 12184769.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Ruthenium_anti-cancer_drugs&oldid=1176595669"